Finally, potentiation of T cell responses was demonstrated in vivo, where anti-PD-1 plus anti-CD73 treatment of MC38 tumor-bearing mice led to improved anti-cancer immune infiltration in the TME, which was predominantly characterized by increased infiltrating CD8+ T cells and decreased tumor burden. The gene discussed is CD8A; the disease is neoplasm.